Latest filings (excl ownership)
15-12B
Securities registration termination
30 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
RW
Registration withdrawal request
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
POS AM
Prospectus update (post-effective amendment)
20 Jul 18
POS AM
Prospectus update (post-effective amendment)
20 Jul 18
POS AM
Prospectus update (post-effective amendment)
20 Jul 18
POS AM
Prospectus update (post-effective amendment)
20 Jul 18
POS AM
Prospectus update (post-effective amendment)
20 Jul 18
POS AM
Prospectus update (post-effective amendment)
20 Jul 18
POS AM
Prospectus update (post-effective amendment)
20 Jul 18
25
Voluntary exchange delisting
17 Jul 18
8-K
Anthera Pharmaceuticals Announces SEC Deregistration
9 Jul 18
8-K
Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request
27 Jun 18
8-K
Departure of Directors or Certain Officers
18 Jun 18
8-K
Other Events
30 May 18
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 May 18
10-Q
2018 Q1
Quarterly report
15 May 18
8-K
Cost Associated with Exit or Disposal Activities
16 Apr 18
EFFECT
Notice of effectiveness
27 Mar 18
8-K
Anthera Pharmaceuticals Reports Top Line Data from
12 Mar 18
S-3
Shelf registration
6 Mar 18
10-K
2017 FY
Annual report
5 Mar 18
8-K
Anthera Pharmaceuticals Provides Business Update and Reports
5 Mar 18
8-K
Anthera Receives Positive Nasdaq Listing Determination
25 Jan 18
D/A
$15M in equity / options, sold $15M, 21 investors
11 Jan 18
8-K
Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering
9 Jan 18
Latest ownership filings
3
Mark Drew McManigle
12 Sep 18
SC 13G/A
Anthera Pharmaceuticals Inc
22 Feb 18
SC 13G/A
Anthera Pharmaceuticals Inc
14 Feb 18
SC 13G/A
Anthera Pharmaceuticals Inc
14 Feb 18
SC 13G/A
Anthera Pharmaceuticals Inc
5 Feb 18
SC 13G
Anthera Pharmaceuticals Inc
18 Jan 18
4
CHRISTOPHER S HENNEY
9 Jan 18
4
PAUL F TRUEX
9 Jan 18
4
Brent Furse
9 Jan 18
4
MAY LIU
9 Jan 18
4
Philip Sager
9 Jan 18
4
JOHN CRAIG THOMPSON
9 Jan 18
4
Brian Mueller
9 Jan 18
4
WILLIAM R SHANAHAN JR
9 Jan 18
4
David E. Thompson
9 Jan 18
SC 13G/A
Anthera Pharmaceuticals Inc
8 Jan 18
SC 13G
Anthera Pharmaceuticals Inc
3 Nov 17
4
JOHN CRAIG THOMPSON
20 Sep 17
4
MAY LIU
15 Sep 17
4
PAUL F TRUEX
7 Sep 17
4
JOHN CRAIG THOMPSON
7 Sep 17
4/A
JOHN CRAIG THOMPSON
7 Sep 17
SC 13G/A
Anthera Pharmaceuticals Inc
11 Jul 17
4
Charles V Olson
22 May 17
4
JOHN CRAIG THOMPSON
22 May 17
4
MAY LIU
22 May 17
4
WILLIAM R SHANAHAN JR
22 May 17
4
Klara Dickinson
22 May 17
4
PAUL F TRUEX
19 May 17
SC 13G/A
Anthera Pharmaceuticals Inc
10 Apr 17
SC 13G
Anthera Pharmaceuticals Inc
20 Mar 17
SC 13G
Anthera Pharmaceuticals Inc
15 Mar 17
4
JOHN CRAIG THOMPSON
3 Mar 17
4/A
JOHN CRAIG THOMPSON
3 Mar 17
SC 13G/A
Anthera Pharmaceuticals Inc
14 Feb 17
SC 13G/A
Anthera Pharmaceuticals Inc
14 Feb 17
SC 13G/A
Anthera Pharmaceuticals Inc
9 Feb 17
5
JOHN CRAIG THOMPSON
6 Feb 17
5
Charles V Olson
6 Feb 17
SC 13G/A
Anthera Pharmaceuticals Inc
19 Jan 17